The 340B Peer-to-Peer Program was created in 2011 by the HRSA Office of Pharmacy Affairs (OPA) and the American Pharmacists Association (APhA) to spotlight high performing 340B entities and recognize them as Leading Practice Sites. Recognized sites provide practical examples of excellence in 340B integrity and quality and serve as a resource for other 340B entities. The program strengthens pre- and post-graduate training of the next generation of pharmacists in 340B, promotes the expansion of clinical pharmacy services in underserved communities, and allows covered entities to share their experiences with the 340B Program with APhA, OPA, and other stakeholders.
The main vehicle in which Leading Practice Sites (LPS) communicate their experiences with stakeholders is through the 340B Peer-to-Peer webinar series. Peer-to-Peer webinars are held at least once a month unless otherwise specified. Peer Mentors from the recognized LPS present on timely topics in an interactive format available to all 340B stakeholders.
All Leading Practice Sites are 340B-covered entities and are selected because of their attention to 340B Program compliance and exemplary performance in the following areas of practice: access to affordable medications, compliant contract pharmacy, efficient business practices, outcomes-driven pharmaceutical care, program integrity, and quality assurance.
Applications are evaluated on the clinical quality and cost-effectiveness of their services in the following areas:
A Leading Practice Site has well developed mechanisms to improve access to essential medications, including minimizing financial, distribution, illiteracy, and language barriers. Such mechanisms are documented in policies and procedures which are monitored and periodically updated to demonstrate patients have access to affordable medications.
A Leading Practice Site has well-developed, documented and monitored systems and practices in place that promote uniform service-levels and that demonstrate optimal management of pharmacy program resources.
A Leading Practice Site promotes outcomes-driven pharmaceutical care through the collaboration with the patient, the pharmacist, and the healthcare team to promote health through medication management, collaborative agreements, and analysis of patient and health system outcomes.
A Leading Practice Site has a culture of compliance and adheres to all applicable federal, state, and local laws and regulations as well as contract requirements with all public and private payers. This culture includes scheduled reviews and updates of diversion avoidance strategies, HRSA/state-compliant duplicate discount avoidance, accuracy of OPA database information, compliance with entity type-specific prohibitions, and forward-looking surveillance and intelligence to update policies and procedures to accommodate emerging legislative and policy changes.
A Leading Practice Site has well-developed, documented and monitored systems in place that ensure patient safety and promote patient satisfaction through the demonstrable management of continuous quality assessment and improvement strategies within their pharmacy program.
A Leading Practice Site, through the use of a contract pharmacy or pharmacies, increases patients’ access to affordable medications and comprehensive pharmacy services while ensuring the prevention of diversion and duplicate discounts. The covered entity must maintain responsibility and auditability of the 340B program through the use of self-compliance checks, independent audits, and comprehensive pharmacy contract models allowing for the verification of eligible 340B patients and prescriptions.
340B covered entities listed in the 340B database as participating 340B entities are eligible to apply. Eligible entities of all sizes and types are encouraged to apply for the prestigious status as a 340B Peer-to-Peer Leading Practice Site.
340B participating entities selected to become Peer-to-Peer leading practice sites will receive:
$20K stipend for two years of participation
Acknowledgement in publications
American Pharmacists Association membership for three leadership team members
Financial support for select conference attendance to represent 340B stakeholders
A participation plaque